Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Neubauer

Showing results (121-130 of 224) with videos related to

Pageof 23
Sort By:
Journal of Hematology & Oncology|July 10, 2019
Nuclear factor of activated T-cells, NFATC1, governs FLT3<sup>ITD</sup>-driven hematopoietic stem cell transformation and a poor prognosis in AMLMaria Solovey, Ying Wang, Christian Michel, et al.
Nucleic Acids Research|May 27, 2024
IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cellsSabrina Fischer, Lisa Marie Weber, Bastian Stielow, et al.
Blood|October 24, 2002
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemiaAndreas Burchert, Stefan Wölfl, Manuel Schmidt, et al.
Blood|July 16, 2005
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemiaMatthias Stelljes, Martin Bornhauser, Matthias Kroger, et al.
British Journal of Haematology|May 23, 2019
Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, et al.
British Journal of Haematology|February 26, 2013
Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemiaBrigitte Mohr, Johannes Schetelig, Kerstin Schäfer-Eckart, et al.
European Journal of Haematology|July 18, 2024
Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapyFabian Acker, Jörg Chromik, Emily Tiedjen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2005
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)Georg Lenz, Martin Dreyling, Eva Hoster, et al.
Annals of Hematology|January 30, 2021
Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysisTobias Wertheimer, Marius Dohse, Gabriel Afram, et al.
Leukemia|September 14, 2021
Publisher Correction: The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)Andreas Neubauer, Johannes Johow, Elisabeth Mack, et al.
Pageof 23

Showing results (121-130 of 224) with videos related to

Sort By:
Pageof 23
Journal of Hematology & Oncology|July 10, 2019
Nuclear factor of activated T-cells, NFATC1, governs FLT3<sup>ITD</sup>-driven hematopoietic stem cell transformation and a poor prognosis in AMLMaria Solovey, Ying Wang, Christian Michel, et al.
Nucleic Acids Research|May 27, 2024
IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cellsSabrina Fischer, Lisa Marie Weber, Bastian Stielow, et al.
Blood|October 24, 2002
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemiaAndreas Burchert, Stefan Wölfl, Manuel Schmidt, et al.
Blood|July 16, 2005
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemiaMatthias Stelljes, Martin Bornhauser, Matthias Kroger, et al.
British Journal of Haematology|May 23, 2019
Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, et al.
British Journal of Haematology|February 26, 2013
Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemiaBrigitte Mohr, Johannes Schetelig, Kerstin Schäfer-Eckart, et al.
European Journal of Haematology|July 18, 2024
Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapyFabian Acker, Jörg Chromik, Emily Tiedjen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2005
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)Georg Lenz, Martin Dreyling, Eva Hoster, et al.
Annals of Hematology|January 30, 2021
Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysisTobias Wertheimer, Marius Dohse, Gabriel Afram, et al.
Leukemia|September 14, 2021
Publisher Correction: The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)Andreas Neubauer, Johannes Johow, Elisabeth Mack, et al.
Pageof 23